Predict your next investment

Venture Capital
zjventure.com

See what CB Insights has to offer

Investments

43

Portfolio Exits

5

Funds

1

About ZJSTIC

Shanghai Zhangjiang Science & Technology Investment Corporation (ZJSTIC) is a venture capital firm that is the main executive unit for the implementation of investment strategy made by Zhangjiang High-tech Park.

ZJSTIC Headquarter Location

Suite 810 No.780 Cailun Road, Zhangjiang High Tech Park

Shanghai, Shanghai,

China

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest ZJSTIC News

Anpac Bio-Medical Science raises over $2 mln

Dec 28, 2015

Shanghai Zhangjiang Science &Technology Investment Corp., along with private investors, have invested over $2 million in Anpac Bio-Medical Science Co. Anpac Bio-Medical is developing an early cancer screening and detection technology. PRESS RELEASE SACRAMENTO, Calif., Dec. 24, 2015 /PRNewswire/ — Anpac Bio-Medical Science Co., Ltd., Chief Executive Officer Dr. Chris Yu announced that Venture Capital (VC) Firm, Shanghai Zhangjiang Science &Technology Investment Corporation (ZJSTIC), as well as private investors related to the insurance industry, have again invested over $2 Million to support Anpac’s “Cancer Differentiation Analysis” (CDA) technology. Impressed by promising results generated from over 25,000 CDA cases to date, the bio-tech-focused VC group and strategic insurance industry leaders invested the equivalency of several million U.S. dollars in 2015, supporting technology listed as, “game changing” and “breakthrough”, in Nobel Prize Laureate Summit on Biomedical Science publications. Anpac’s proprietary CDA technology effectively reinvents cancer screening and early detection by analyzing simple, standard, non-invasive “Blood Biopsies” – resulting in measurably greater detection sensitivity and specificity, with no harmful side effects in patients. The results of 25,000 cases to date demonstrate CDA’s research validity achieving an average sensitivity and specificity rate range of 75%-90% for ten different types of cancer — often identifying the type and location of diseased cells before tumors form. Although a young company, Anpac’s encouraging CDA findings have led to ongoing collaborations and partnerships with nearly 140 cooperative medical institutions; establishing operations networks that include sample collection, storage, logistics, and sales, in 27 Chinese provinces and four municipalities. ZJSTIC leaders project Anpac’s CDA will be the primary cancer screening method serving much of China’s population within five years – and thus an excellent investment opportunity. Partly as a result of ZJSTIC’s significant “Series B” investment, Anpac is now establishing a U.S. Headquarters, forming American partnerships, and initiating U.S. FDA clinical trials. “Anpac has made significant progress validating its innovative, ‘game-changing’, CDA technology,” states Yu. “We continue to demonstrate CDA’s multiple advantages over existing technologies; especially in its ease of use and effectiveness detecting early stage cancer through higher sensitivity and specificity, without any side effects. Anpac will use our latest investments to further CDA research and operations in the United States. We are already executing our second round of hiring, establishing partnerships, building multiple labs, and preparing to expedite FDA clinical trials. We are proud our backers continue to reinvest in our company, due to CDA’s consistent and ever-increasing effectiveness and success.” For further information: Anpac Bio-Medical Science Company, Ltd.: http://www.anpac.cn/IndexEn.htm; ZJSTIC:http://www.zjventure.com/. Logo – http://photos.prnewswire.com/prnh/20151224/318127LOGO SOURCE Anpac Bio-Medical Science Company, Ltd. © 2015 Buyouts Insider / Argosy Group LLC

ZJSTIC Investments

43 Investments

ZJSTIC has made 43 investments. Their latest investment was in PPIO as part of their Series A on December 12, 2021.

CBI Logo

ZJSTIC Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/2/2021

Series A

PPIO

$15.7M

Yes

7

9/17/2021

Series A - II

SynSense

$30.93M

Yes

1

8/4/2021

Series A

Longwell Robot

Yes

1

5/27/2021

Corporate Minority

Subscribe to see more

Subscribe to see more

10

5/19/2021

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/2/2021

9/17/2021

8/4/2021

5/27/2021

5/19/2021

Round

Series A

Series A - II

Series A

Corporate Minority

Series A - II

Company

PPIO

SynSense

Longwell Robot

Subscribe to see more

Subscribe to see more

Amount

$15.7M

$30.93M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

7

1

1

10

10

ZJSTIC Portfolio Exits

5 Portfolio Exits

ZJSTIC has 5 portfolio exits. Their latest portfolio exit was ASR Microelectronics on January 14, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/14/2022

IPO

$99M

1

11/18/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

1/30/2020

IPO

Subscribe to see more

Subscribe to see more

10

1/30/2020

IPO

Subscribe to see more

Subscribe to see more

10

11/18/2010

IPO

Subscribe to see more

Subscribe to see more

10

Date

1/14/2022

11/18/2021

1/30/2020

1/30/2020

11/18/2010

Exit

IPO

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

ZJSTIC Fund History

1 Fund History

ZJSTIC has 1 fund, including Sino-century Venture Capital Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/1/2007

Sino-century Venture Capital Fund

Multi-Stage Venture Capital

Closed

$185.1M

1

Closing Date

12/1/2007

Fund

Sino-century Venture Capital Fund

Fund Type

Multi-Stage Venture Capital

Status

Closed

Amount

$185.1M

Sources

1

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.